A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - Trial NCT06312137
Access comprehensive clinical trial information for NCT06312137 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp & Dohme LLC and is currently Recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 780 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Merck Sharp & Dohme LLC
Timeline & Enrollment
Phase 3
Apr 03, 2024
Oct 23, 2034
Primary Outcome
Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR)
Summary
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is
 effective in treating NSCLC for participants not achieving pathological complete response.
 The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is
 superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed
 by blinded independent central review (BICR).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06312137
Non-Device Trial